New study aims to crack the code on drug sequencing for advanced breast cancer
NCT ID NCT07162259
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times
Summary
This study looks at 40 people with a common type of advanced breast cancer (HR+/HER2-) that has stopped responding to standard hormone therapy. Researchers want to find the best order to give two powerful drugs, called ADCs, to control the cancer longer and with fewer side effects. The goal is to help doctors make smarter treatment choices based on each person's unique cancer markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xi'an International Medical Center Hospital
Xi'an, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.